Physician
Endocrinology
Dr. Verena M. Hug, MD
|
|
Give Review
Verena practices Endocrinology. She went to medical school at Baylor College of Medicine. Doctor Verena M. Hug, MD is also published. She has 54 publications published. The lastest publication: "The clonogenic growth of advanced breast tumour lesions adds no value to that of established clinical prognosticators for survival.'
Publications
- Regulation of insulin receptor gene expression. Cell cycle-mediated effects on insulin receptor mRNA stability.
- Chemosensitivities of human clonogenic breast tumor cells.
- Role of culture conditions and exposure duration in determining sensitivity of human bone marrow progenitor cells to methotrexate.
- Phase II study of iproplatin in metastatic breast carcinoma.
- Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast Cancer unresponsive to hormonal therapy.
- Use of growth-stimulatory hormones to improve the in vitro therapeutic index of doxorubicin for human breast Tumors.
- Unusual toxicity of doxorubicin infusion.
- Phase II evaluation of Ly156758 in metastatic breast Cancer.
- Cisplatin in combination with continuous infusion vinblastine for refractory breast Cancer.
- Chemoresistance is not a cause of the apparent failure of adjuvant chemotherapy in postmenopausal women.
- Clonogenic growth and hormone sensitivity of benign and malignant breast tissues.
- Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast Cancer. A prospective, randomized trial.
- Chemotherapy and hormonal therapy in combination.
- Mitomycin for treatment of brain parenchymal disease.
- Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast Cancer.
- Adjuvant therapy of breast Cancer with or without additional treatment with alternate drugs.
- Oral medroxyprogesterone acetate in the treatment of metastatic breast Cancer.
- Management of stage III primary breast Cancer with primary chemotherapy, surgery, and radiation therapy.
- Predictors of hormone response for patients with ER-unknown breast tumours.
- Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
- Body weight and breast Cancer.
- Sequential cyclic combined hormonal therapy for metastatic breast Cancer.
- Is chemotherapy effective in reducing the local failure rate in patients with operable breast Cancer?
- Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience.
- Adrenal failure in patients with breast carcinoma after long-term treatment of cyclic alternating oestrogen progesterone.
- Clinical course of patients with breast Cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy.
- The clonogenic growth of advanced breast tumour lesions adds no value to that of established clinical prognosticators for survival.
- Nuclear protein-binding analysis of a GC-rich insulin-receptor promoter regulatory region.
- The results of modified use of chemotherapy for patients with metastatic breast Cancer.
- Dexamethasone mediated stabilization of insulin receptor mRNA.
- Sequence and functional characterization of the terminal exon of the human insulin receptor gene.
- A phase II study of peptichemio in advanced breast Cancer.
- [Oral hygiene in the proximal space].
- Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofur...
- The true predictive value of the human tumor stem cell assay: does a workable assay select for treatment responders?
- Normalization of in vitro sensitivity testing of human tumor clonogenic cells.
- Growth factor enhancement of the in vitro stem cell assay.
- Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count.
- Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast Cancer previously treated with...
- Dose-survival curves of cis-platinum, melphalan, and velban in human granulocyte/macrophage progenitor cells.
- Improved culture conditions for clonogenic growth of primary human breast tumours.
- Responses of human bone marrow progenitor cells to fluoro-ara-AMP, homoharringtonine, and elliptinium.
- Effect of diethylaminoethyl-dextran on colony formation of human tumor cells in semisolid suspension cultures.
- [Status of the hospital aide within the nursing team].
- Regulation of breast tumor growth by high dose estrogen is independent of the presence of estrogen receptors.
- Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro.
- Effect of cyclophosphamide on the mitomycin-induced syndrome of thrombotic thrombocytopenic purpura.
- Clonogenic in vitro growth and histologic grading of primary human breast Tumors.
- The human tumor stem cell assay revisited.
- Survival of human bone marrow cells after in vitro treatment with 12 antiCancer drugs and implications for tumor drug sensitivity assays.
- Effects and interactions of epidermal growth factor, insulin, hydrocortisone, and estradiol on the cloning of human tumor cells.
- In vitro cytotoxicity patterns of standard and investigational agents on human bone marrow granulocyte-macrophage progenitor cells.
- Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast Cancer.
Conditions Treated
- Anemia
- Neuroendocrine Tumors
- Thyroid Cancer
Doctors Specialties
- Medical Oncology
- Oncology
- Endocrinology
Accepted Insurances
Education
-
Baylor College of Medicine -
University of Texas MD Anderson Cancer Center -
University of Bern Faculty of Medicine
Drug Facts
| NPI NUMBER | 1164554390 | |
| NPPES Provider LastName | HUG | |
| NPPES Provider FirstName | VERENA | |
| NPPES Provider ZIPCode | 770301312 | |
| NPPES Provider State | TX | |
| Specialty Description | Endocrinology | |
| Total Claim Count | 142.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1164554390 |
| Last Name Of The Provider | HUG |
| First Name Of The Provider | VERENA |
| View All |
Similar Doctors
|
Dr. Amir Hassan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Phillips K. Champion Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne Tsao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria E. Cabanillas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sharon M. Giordano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jasmine Boparai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Waun K. Hong, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Susan M. O'Brien, MD |
|
|
Dr. Yee L. Tham, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Luis S. Acosta, MD |
|
|
Dr. Daniel S. Tung, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sonali N. Thosani, MD
This Doctor is OpenDoctor Recommended.
|